Fig 3. Relationship between MAP2K1 class, clinical features, and survival. (A) PFS and (B) OS in class 2 versus other MAP2K1 mutant tumors in the whole MAPK targeted therapy-treated cohort. (C) PFS ...
Correlates of Cetuximab Efficacy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Previously Treated With Immunotherapy MAP2K1/MEK1 mutations are potentially actionable drivers in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback